Stemline Therapeutics (STML) Tops Q3 EPS by 6c

Stemline Therapeutics (NASDAQ: STML) reported Q3 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59).

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Cisco rating cut at HSBC as analyst sees a lack of catalysts